PACIRA BIOSCIENCES, INC. Operating Lease Cost
PACIRA BIOSCIENCES, INC. (PCRX) reported Operating Lease Cost of $3.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. operating lease, cost for the quarter ending 2026-06-30 was $3.19M, a 1.36% decline year-over-year.
- PACIRA BIOSCIENCES, INC. operating lease, cost for the quarter ending 2026-03-31 was $3.13M, a 5.06% decline year-over-year.
- PACIRA BIOSCIENCES, INC. operating lease, cost for the quarter ending 2025-12-31 was $3.11M, a 10.12% decline year-over-year.
- PACIRA BIOSCIENCES, INC. operating lease, cost for the quarter ending 2025-09-30 was $3.14M, a 9.25% decline year-over-year.
- PACIRA BIOSCIENCES, INC. operating lease, cost for fiscal 2025 was $12.78M, a 7.88% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. operating lease, cost for fiscal 2024 was $13.88M, a 3.26% decline from fiscal 2023.
- PACIRA BIOSCIENCES, INC. operating lease, cost for fiscal 2023 was $14.34M, a 2.83% increase from fiscal 2022.
- PACIRA BIOSCIENCES, INC. operating lease, cost for fiscal 2022 was $13.95M, a 16.47% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.19M 10-Q · filed 2026-08-04 | $6.32M 10-Q · filed 2026-08-04 | $9.43M derived: sum of 3 quarters · filed 2026-08-04 | $12.57M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $3.13M 10-Q · filed 2026-04-30 | $6.25M derived: sum of 2 quarters · filed 2026-04-30 | $9.38M derived: sum of 3 quarters · filed 2026-04-30 | $12.62M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $3.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.25M derived: sum of 2 quarters · filed 2026-02-26 | $9.48M derived: sum of 3 quarters · filed 2026-08-04 | $12.78M 10-K · filed 2026-02-26 |
| 2025-09-30 | $3.14M 10-Q · filed 2025-11-06 | $6.37M derived: sum of 2 quarters · filed 2026-08-04 | $9.67M 10-Q · filed 2025-11-06 | $13.13M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $3.23M 10-Q · filed 2026-08-04 | $6.53M 10-Q · filed 2026-08-04 | $9.99M derived: sum of 3 quarters · filed 2026-08-04 | $13.45M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $3.30M 10-Q · filed 2026-04-30 | $6.76M derived: sum of 2 quarters · filed 2026-04-30 | $10.22M derived: sum of 3 quarters · filed 2026-04-30 | $13.68M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.92M derived: sum of 2 quarters · filed 2026-02-26 | $10.38M derived: sum of 3 quarters · filed 2026-02-26 | $13.88M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.46M 10-Q · filed 2025-11-06 | $6.92M derived: sum of 2 quarters · filed 2025-11-06 | $10.42M 10-Q · filed 2025-11-06 | $13.94M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $3.46M 10-Q · filed 2025-08-05 | $6.96M 10-Q · filed 2025-08-05 | $10.48M derived: sum of 3 quarters · filed 2026-02-26 | $14.04M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $3.50M 10-Q · filed 2025-05-08 | $7.02M derived: sum of 2 quarters · filed 2026-02-26 | $10.58M derived: sum of 3 quarters · filed 2026-02-26 | $14.21M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.08M derived: sum of 2 quarters · filed 2026-02-26 | $10.72M derived: sum of 3 quarters · filed 2026-02-26 | $14.34M 10-K · filed 2026-02-26 |
| 2023-09-30 | $3.56M 10-Q · filed 2024-11-06 | $7.19M derived: sum of 2 quarters · filed 2024-11-06 | $10.82M 10-Q · filed 2024-11-06 | $14.26M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $3.63M 10-Q · filed 2024-07-30 | $7.26M 10-Q · filed 2024-07-30 | $10.70M derived: sum of 3 quarters · filed 2025-02-27 | $14.14M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $3.63M 10-Q · filed 2024-05-07 | $7.07M derived: sum of 2 quarters · filed 2025-02-27 | $10.51M derived: sum of 3 quarters · filed 2025-02-27 | $14.05M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $6.88M derived: sum of 2 quarters · filed 2025-02-27 | $10.42M derived: sum of 3 quarters · filed 2025-02-27 | $13.95M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.44M 10-Q · filed 2023-11-02 | $6.98M derived: sum of 2 quarters · filed 2023-11-02 | $10.51M 10-Q · filed 2023-11-02 | $13.72M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $3.54M 10-Q · filed 2023-08-02 | $7.07M 10-Q · filed 2023-08-02 | $10.28M derived: sum of 3 quarters · filed 2024-02-29 | $13.20M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $3.53M 10-Q · filed 2023-05-03 | $6.74M derived: sum of 2 quarters · filed 2024-02-29 | $9.66M derived: sum of 3 quarters · filed 2024-02-29 | $12.58M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $6.13M derived: sum of 2 quarters · filed 2024-02-29 | $9.05M derived: sum of 3 quarters · filed 2024-02-29 | $11.98M 10-K · filed 2024-02-29 |
| 2021-09-30 | $2.92M 10-Q · filed 2022-11-03 | $5.84M derived: sum of 2 quarters · filed 2022-11-03 | $8.76M 10-Q · filed 2022-11-03 | $11.73M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $2.92M 10-Q · filed 2022-08-03 | $5.84M 10-Q · filed 2022-08-03 | $8.81M derived: sum of 3 quarters · filed 2023-02-28 | $11.91M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $2.92M 10-Q · filed 2022-05-04 | $5.89M derived: sum of 2 quarters · filed 2023-02-28 | $8.99M derived: sum of 3 quarters · filed 2023-02-28 | $11.41M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $6.07M derived: sum of 2 quarters · filed 2023-02-28 | $8.49M derived: sum of 3 quarters · filed 2023-02-28 | $10.05M 10-K · filed 2023-02-28 |
| 2020-09-30 | $3.10M 10-Q · filed 2021-11-03 | $5.52M derived: sum of 2 quarters · filed 2021-11-03 | $7.08M 10-Q · filed 2021-11-03 | $8.77M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $2.42M 10-Q · filed 2021-08-03 | $3.99M 10-Q · filed 2021-08-03 | $5.67M derived: sum of 3 quarters · filed 2022-02-28 | $7.25M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $1.56M 10-Q · filed 2021-05-04 | $3.25M derived: sum of 2 quarters · filed 2022-02-28 | $4.83M derived: sum of 3 quarters · filed 2022-02-28 | $6.35M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.27M derived: sum of 2 quarters · filed 2022-02-28 | $4.78M derived: sum of 3 quarters · filed 2022-02-28 | $6.22M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.58M 10-Q · filed 2020-10-30 | $3.10M derived: sum of 2 quarters · filed 2020-10-30 | $4.54M 10-Q · filed 2020-10-30 | $6.03M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $1.52M 10-Q · filed 2020-08-06 | $2.96M 10-Q · filed 2020-08-06 | $4.45M derived: sum of 3 quarters · filed 2021-03-01 | $7.10M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $1.44M 10-Q · filed 2020-05-07 | $2.93M derived: sum of 2 quarters · filed 2021-03-01 | $5.59M derived: sum of 3 quarters · filed 2021-03-01 | $7.19M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $4.14M derived: sum of 2 quarters · filed 2021-03-01 | $5.75M derived: sum of 3 quarters · filed 2021-03-01 | $7.24M 10-K · filed 2021-03-01 |
| 2018-09-30 | $2.66M 10-Q · filed 2019-11-08 | $4.26M derived: sum of 2 quarters · filed 2019-11-08 | $5.75M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $1.60M 10-Q · filed 2019-08-08 | $3.09M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $1.49M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |